I’m avoiding this iconic FTSE 250 stock in September

This FTSE 250 company has a storied history and a household name brand. So, why am I avoiding it while it’s down substantially?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

This way, That way, The other way - pointing in different directions

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

By definition, the FTSE 250 index is home to future FTSE 100 stocks. Just like the English Football League Championship is home to future Premier League clubs. However, stocks and clubs can also travel in the other direction.

Investing in the right mid-cap share early enough can produce market-thumping returns.

Lost its footing

However, digging through the FTSE 250, I see a handful of names that I’m uncertain about long term. One of them is Dr Martens (LSE:DOCS).

Shares of the bootmaker have been doing well recently, rising 20% in just the past month. However, they’ve still lost half their value since the start of 2023, and more than three-quarters since listing in 2021.

The company has issued multiple profit warnings in recent years, with weak demand and warehousing problems in the US knocking investor confidence in the brand’s prospects. Profits have slumped alarmingly.

Meanwhile, Dr Martens’ fashion appeal has faded, at least for its iconic chunky boots. You don’t have to dig deep on Reddit to find users complaining about poor quality and overpriced products. Back in the day, a pair of Docs could last for life. Not so much nowadays. 

Firmer ground

However, there are green shoots of recovery emerging at the company. Indeed, CEO Ije Nwokorie has even predicted a return to growth in the current financial year (FY26).

In June, he said: “Our single focus in FY25 was to bring stability back to Dr Martens. We have achieved this by returning our direct-to-consumer channel in the Americas back to growth, resetting our marketing approach to focus relentlessly on our products, delivering cost savings, and significantly strengthening our balance sheet.”

The City is currently buying into the turnaround, with revenue forecast to rise from £788m last year to £850m by FY27. Crucially, earnings per share are expected to increase by around 40% over this time, putting the stock on a forward price-to-earnings (P/E) multiple of 16.5.

If the company can keep building from there, then I think a multiyear turnaround in the share price is possible.

Brand messaging

Dr Martens says it aspires to be the “world’s most-desired premium footwear brand“. It wants to be “democratic”, while staying true to its heritage by staying connected to youth culture and subcultural roots.

A cynic might say that the brand wants to have its cake and eat it. A global premium footwear brand doesn’t sound rebellious or subcultural to me.

At a recent punk festival in Blackpool, I asked some old-school punks about the brand. All thought it went ‘woke’ years ago, embarrassed by its historical associations with skinheads, who weren’t exactly known for being politically correct.

Yet, I noted that many still wore Docs out of nostalgia, while some younger people were wearing them. So perhaps the company is doing as well as it can to bridge the generations.

I suspect Asia is where the brand’s future growth might lie. Japan and South Korea are driven by youth fashion culture. Rebellious self-expression is arguably more mainstream there. Symbolically, there are now more Dr Martens stores in Japan (46) than the UK (34).

The stock could be a strong turnaround candidate, though US tariffs are a risk, with most of Dr Martens’ manufacturing done in Asia.

Weighing things up, there’s too much uncertainty for me to invest long term here.

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK supporters with flag
Investing Articles

£1k invested in the UK stock market during the pandemic is currently worth…

Jon Smith not only points out the specific gains from investing in the stock market generally since the pandemic, but…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Will Nvidia shares continue surging in 2026 and beyond?

2026 will be an exciting year for Nvidia shares as the semiconductor giant launches its latest generation of AI chips.…

Read more »

Investing Articles

Check out the BP share price and dividend forecast for 2026 – it’s hard to believe!

Harvey Jones is feeling rather glum about the BP share price but analysts reckon it's good to go. So who's…

Read more »

Investing Articles

I asked ChatGPT for its top FTSE 100 stock for 2026, and it said…

Muhammad Cheema asked ChatGPT for its top FTSE 100 pick, and its response surprised him. He thinks he’s found an…

Read more »

Investing Articles

By the end of 2026, can Rolls-Royce shares hit £17?

Rolls-Royce shares have had another phenomenal year, rising by 95.4%. Muhammad Cheema takes a look at whether they can continue…

Read more »

Investing Articles

Will Barclays shares continue their epic run into 2026 and beyond?

Noting that difference of opinion is a global norm, Zaven Boyrazian discusses what the experts think will happen to Barclays…

Read more »

Investing Articles

Prediction: analysts reckon Taylor Wimpey shares will soar almost 25% in 2026. Seriously?

When it comes to Taylor Wimpey shares, Harvey Jones is the eternal optimist. So will the high-yielding FTSE 250 housebuilder…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Up 83%+ last year, will these FTSE 100 shares do it all again in 2026?

These FTSE 100 stocks delivered share price gains of up to 403% over the last year! Royston Wild reckons they…

Read more »